The central challenge tackled by this research lies in the immunosuppressive nature of myeloid cells—immune cells abundant within glioblastoma tumors—that often dampen the body’s natural anti-cancer responses. These myeloid cells form a protective milieu that enables residual cancer cells to evade destruction after surgical excision, contributing to tumor recurrence. The research team asked whether reprogramming these immune cells immediately after tumor resection could convert this suppressive environment into a pro-inflammatory, cancer-fighting one.

To achieve this, the investigators engineered a wafer-like implant made of crosslinked cyclodextrin, a sugar-based, biodegradable polymer capable of sustained drug release. This implant, aptly nicknamed CANDI, is designed to be placed in the brain cavity created after tumor removal surgery. Its slow-release mechanism delivers a potent cocktail of small molecule immune modulators directly to the myeloid cells infiltrating the surgical site. By precisely targeting myeloid cells in situ, the wafer aims to enhance local immune activation without systemic toxicity.

Initial in vitro experiments confirmed that the cyclodextrin wafer not only successfully released the immune-modulating agents but was also effectively engulfed by tumor-associated macrophages—key myeloid cells in glioblastoma. Upon internalization, these immune cells were reprogrammed to produce interleukin-12 (IL-12), a cytokine critical for stimulating robust anti-tumor immunity. IL-12 promotes the recruitment and activation of cytotoxic T cells, boosting the immune system’s ability to eradicate remaining glioblastoma cells.

In vivo studies in mouse models of glioblastoma provided compelling evidence for the wafer’s efficacy. When implanted following surgical tumor removal, CANDI resulted in long-term tumor-free survival in over half of the mice treated, a remarkable improvement compared to controls. Immune profiling confirmed increased infiltration and activation of T cells at the tumor site, validating the immune-modulating strategy’s ability to transform the tumor microenvironment from immunosuppressive to immunostimulatory.

Crucially, the team extended their investigations to freshly harvested human glioblastoma tissues maintained ex vivo, demonstrating that the wafer induced similar immunological changes in human tumors. This translational aspect strengthens the potential clinical relevance of the implant-mediated therapy and signals feasibility for eventual human trials.

This breakthrough holds substantial implications for the future of glioblastoma treatment. While immunotherapies have revolutionized management of various cancers, no FDA-approved immunotherapy yet exists for glioblastoma due to its highly immunosuppressive microenvironment and poor drug delivery across the blood-brain barrier. By directly implanting an immunomodulatory device into the surgical cavity, this approach circumvents systemic delivery challenges and may complement existing standards of care, such as chemo- and radiotherapy, potentially extending patient survival and improving quality of life.

Looking ahead, the researchers are focused on refining the wafer’s design to optimize drug release kinetics for human applications and scaling up production consistent with clinical manufacturing standards. They are preparing to enter phase I clinical trials, with the goal of integrating this implantable immunotherapy into surgical oncology protocols in the near future.

The publication credits Christopher S. Garris, Hyung Shik Kim, Juhyun Oh, Elias A. Halabi, Moonhyun Choi, Sepideh Parvanian, and Rainer Kohler as co-authors, emphasizing the collaborative interdisciplinary efforts that made this innovation possible. Financial support was provided by grants from the National Institutes of Health, as well as the Swiss Institute for Experimental Cancer Research and the German Academic Exchange Service.

This pioneering strategy exemplifies how converging advances in biomaterials, immunology, and neurosurgery can yield transformative therapies for some of medicine’s most intractable diseases. If successful in human trials, the CANDI implant could mark a paradigm shift in glioblastoma management, leveraging the body’s own immune arsenal to prevent cancer relapse in a disease that has long defied durable control.

Such implant-mediated immunotherapies may soon extend beyond glioblastoma to other solid tumors characterized by immunosuppressive microenvironments, broadening the therapeutic impact of this novel modality. As this research progresses, it reinforces the critical role of local immune modulation in enhancing cancer control and the promise of biomaterials to precisely deliver such interventions.

This study stands at the forefront of personalized medicine, transforming the surgical bed from a vulnerable site of residual disease into a battleground of immune-mediated tumor eradication. The innovation paves the way for integrating immunotherapy directly into surgical practice, potentially revolutionizing outcomes for patients afflicted by devastating cancers like glioblastoma.

Subject of Research: Animals
Article Title: Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence
News Publication Date: 22-Oct-2025
Web References: DOI: 10.1038/s41551-025-01533-2
References: Kaiser, Y., et al. Nature Biomedical Engineering, 2025
Image Credits: Not provided

Stroke, a leading cause of long-term disability worldwide, traditionally centers medical intervention on physical rehabilitation—restoring movement, strength, and neurological function. However, Dr. Yechoor and her team highlight profound emotional and psychosocial dimensions that are often sidelined in clinical practice. By using qualitative research methods, the study delves deep into the narratives of 41 stroke survivors and their caregivers across the United States, collected between October 2023 and December 2024. This approach offers an intimate perspective on the multi-layered journey of recovery that transcends just physical healing.

The central aim of the research was to dissect the elements constituting both physical and emotional wellbeing post-stroke, then evaluate how well these dimensions align with existing clinical assessment tools. Specifically, they contrasted survivors’ self-reported experiences with the Stroke Specific Quality of Life (SSQoL) scale—an instrument ubiquitous in stroke research and clinical monitoring. The comparison revealed striking insights into what aspects of recovery are well-measured and, more importantly, which critical emotional components remain unaddressed.

Stroke survivors articulated that beyond the pursuit of regaining physical mobility, emotional recovery holds equal, if not greater, significance. They reported dealing with pervasive feelings of stigma, uncertainty about their future, loss of identity, and diminished social participation. These emotional burdens manifest as a constellation of five key factors challenging recovery: loss of independence, fear stemming from unpredictability, restricted community engagement, pervasive shame, and decreased physical mobility. While the SSQoL scale effectively captures elements related to physical functioning and social participation, it inadequately reflects the nuanced emotional states of shame and uncertainty.

This revelation underscores a significant care gap in the post-stroke continuum. Traditional care models predominantly target neurological and physical restoration, often neglecting the intangible yet profound psychological hurdles that survivors encounter daily. Addressing this gap requires a paradigm shift: clinicians and researchers must incorporate the lived experiences of stroke survivors more holistically into both assessment and therapy frameworks.

The study’s implications extend beyond measurement inadequacies to the broader development of stroke rehabilitation models. Partnering with stroke survivors and caregivers, Dr. Yechoor’s team advocates for patient-centered care pathways that prioritize emotional resilience and psychological health on par with physical recovery. This inclusive model would involve creating interventions co-designed by patients, enhancing relatability and efficacy.

Looking forward, the research group plans to translate their qualitative insights into actionable clinical interventions. An essential aspect of this next phase is the integration of patient and caregiver perspectives during intervention design, ensuring that new therapeutic approaches resonate with the priorities and lived realities of those recovering from stroke. This method rests on the principle that understanding a patient’s holistic experience, rather than exclusively focusing on clinical metrics, leads to more meaningful and sustained recovery outcomes.

Crucially, the study contributes to shifting the scientific discourse in stroke research. It challenges researchers to rethink how recovery is defined and measured, advocating for multidimensional metrics that encompass physical, emotional, and social domains. The recognition of emotional wellbeing as a cornerstone of stroke rehabilitation encourages multidisciplinary collaboration, including neurologists, psychologists, social workers, and rehabilitation therapists, to craft integrated care models.

The authors acknowledge the critical role of stroke survivors and their caregivers who participated in the research. Their candid narratives and resilience not only enriched the data quality but also serve as a clarion call to healthcare systems to prioritize comprehensive recovery. Their partnership exemplifies how patient engagement can dramatically enhance research relevance and clinical impact.

This innovative work was made possible with support from the Bugher Collaborative Project and various brain health innovation funds, highlighting the growing emphasis on neurological research that goes beyond the biological underpinnings to embrace psychosocial complexity. The authors’ affiliations and disclosures indicate a robust network of collaboration spanning major research institutes, reflecting the study’s credibility and scientific rigor.

Dr. Yechoor’s study represents a paradigm transformation in stroke care, one that aligns recovery with real human experience rather than narrowly defined clinical outcomes. By bringing emotional health to the forefront of stroke recovery dialogue, this research paves the way for developing more compassionate, effective, and personalized therapeutic approaches that could ultimately improve quality of life for millions of stroke survivors worldwide.

As the healthcare community digests these findings, there is hope that new comprehensive stroke care models will emerge that are better attuned to the needs of survivors. The continued partnership between patients, caregivers, and clinicians will be vital to this evolution, ensuring that future research and interventions address the full spectrum of recovery.

This study not only advances scientific understanding but also elevates the voices of stroke survivors, reminding the field that successful recovery is a multifaceted, deeply personal journey. Recognizing and incorporating these voices fosters a much-needed humanistic approach in neurology and rehabilitation medicine, underscoring the importance of empathy, inclusivity, and holistic care.

Subject of Research: People
Article Title: “Coherence of Stroke Survivors’ Lived Experiences and the Stroke Specific Quality of Life Scale”
News Publication Date: 17-Oct-2025
Web References: DOI: 10.1001/jamanetworkopen.2025.3795
References: Choksi, D., et al. “Coherence of Stroke Survivors’ Lived Experiences and the Stroke Specific Quality of Life Scale” JAMA Network Open. DOI: 10.1001/jamanetworkopen.2025.3795
Image Credits: Not provided

Keywords: cerebrovascular disorders, stroke recovery, emotional wellbeing, quality of life, stroke specific quality of life scale, patient-centered care, rehabilitation, caregiver support, neurological disorders

The immune system’s ability to recognize and eliminate cancer cells hinges on effective antigen presentation, a process primarily mediated by the human leukocyte antigen class I (HLA-I) complex. Tumor antigens are processed and presented on HLA-I molecules on the cancer cell surface, flagging aberrant cells for destruction by CD8+ cytotoxic T lymphocytes. Paradoxically, BCC cells suppress the expression of HLA-I, effectively cloaking themselves in immunological invisibility. This suppression results from a sophisticated epigenomic mechanism connected to the tumor’s cell of origin and its intrinsic stemness programs.

Dr. Demehri’s team meticulously compared BCC samples to cutaneous squamous cell carcinomas (SCCs), which exhibit higher responsiveness to immune checkpoint inhibitors. Through single-cell RNA sequencing and histological analyses, they demonstrated that BCCs harbor an "immune-excluded" microenvironment, characterized by minimal infiltration of CD4+ and CD8+ T cells within tumor foci. This contrasts sharply with SCCs, where immune cells readily penetrate the tumor stroma. The immune exclusion observed in BCC correlates tightly with the downregulation of antigen presentation machinery (APM), evident even at early disease stages, suggesting an inherent, developmental basis for immune evasion.

Central to this suppression is the transcription factor Foxc1, which is normally involved in maintaining quiescence of hair follicle stem cells — the presumptive cell of origin for BCC. Foxc1 directly represses genes encoding key components of the APM, including HLA-I and interferon regulatory factor 1 (IRF1), through epigenomic modifications that silence their expression. This pharmacologically reversible epigenetic repression provides a molecular explanation for why BCCs, despite their heavy mutational load, remain largely undetected and refractory to immune attack.

The clinical implications of these discoveries are profound. Dr. Demehri’s research shows that topical application of entinostat, a histone deacetylase inhibitor, can epigenetically reverse APM suppression in BCC cells in vivo. When used in combination with imiquimod, a topical immune response modifier approved for skin cancers, entinostat significantly enhances antigen presentation and stimulates immune cell infiltration, producing a synergistic antitumor effect. This dual-regimen effectively overcomes the immune exclusion barrier, transforming BCC from an immunologically "cold" tumor into one more amenable to immune-mediated clearance.

Such findings challenge the existing paradigm that high tumor mutational burden necessarily predicts immunotherapy success. Instead, they emphasize the pivotal role of a cancer’s cellular and epigenetic context, particularly the intrinsic stemness programs inherited from their cell of origin, in dictating immunogenicity. By targeting these epigenomic regulators, it may be possible to sensitize otherwise resistant tumors to immune-based treatments, broadening the therapeutic horizon beyond BCC.

Beyond immediate treatment strategies, this work raises critical questions about how tissue-specific stemness pathways modulate tumor-immune interactions more broadly. Could similar epigenetic constraints on antigen presentation operate in other cancers arising from quiescent stem cell populations? If so, unraveling these intrinsic immunosuppressive mechanisms may unlock new generalizable approaches to cancer immunotherapy.

Furthermore, these insights offer hope for organ transplant recipients and immunosuppressed patients, who are disproportionately susceptible to SCC yet relatively spared from BCC development. This differential risk underscores the clinical relevance of BCC’s low immunogenicity and may inform personalized surveillance and therapeutic strategies for high-risk populations.

In essence, this study elegantly combines molecular immunology, epigenomics, and clinical oncology to redefine our understanding of tumor immune evasion. The identification of Foxc1 as a master regulator of antigen presentation heralds a new chapter in skin cancer research and immunotherapy, anchored in the biology of the tumor’s origin rather than mutation burden alone.

Looking forward, Dr. Demehri and colleagues advocate for clinical trials testing the efficacy and safety of entinostat-primed immunotherapy in patients with BCC. Such trials could validate this novel combination as a frontline or adjunct treatment, potentially improving outcomes for thousands of patients afflicted with this common yet challenging cancer.

This research exemplifies the power of combining cutting-edge single-cell technologies with translational oncology to unravel the complex interplay between cancer cell states and immune recognition. As the field of cancer immunotherapy continues to evolve, studies like this underscore the importance of considering tumor cell origin and epigenetic regulation when designing effective treatments.

In conclusion, the elucidation of epigenomic mechanisms governing stemness and immune suppression opens promising avenues not only for the treatment of basal cell carcinoma but also for a broader understanding of cancer immunobiology. By leveraging these insights, the oncology community stands poised to overcome longstanding barriers in combating immune-resistant tumors, heralding a new era of precision medicine and immunotherapy.

Subject of Research: Cells

Article Title: Epigenomic regulation of stemness contributes to the low immunogenicity of the most mutated human cancer

News Publication Date: 17-Apr-2025

Web References:

• https://www.cell.com/cell-reports/fulltext/S2211-1247(25)00332-8
• http://dx.doi.org/10.1016/j.celrep.2025.115561

Image Credits: Shawn Demehri, Massachusetts General Hospital

Keywords: Skin cells, Immunogenicity, Combination therapies, Cancer immunotherapy